OccuLogix keeps an eye on new dry AMD (age-related macular degeneration) therapy
This article was originally published in Clinica
TLC Vision and Vascular Sciences have formed a 50:50 joint venture, OccuLogix, that will focus on commercialising Vascular Sciences' new blood filtration method for treating dry age-related macular degeneration (AMD) - the leading cause of blindness in the over 50s in the Western world.
You may also be interested in...
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.
AstraZeneca's research head admits that the half dose approach was a lucky mistake – but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.